Oncolytic adenovirus armed w immune stimulating transgene targeting basket of I-O indications. Strong results from Part 1 (ONCOS-102/Keytruda combo) trial in anti-PD1 refractory melanoma: 33% ORR in 9 pts: 1 CR, 2 PRs; immune act. in all 9 pts. Upcoming milestones: randomized data, Ph 1b/2 (mesothelioma, n=31) w/chemo: Jan 2020; Ph 1, Part 2 data (melanoma comb w/Keytruda, n=21): 1H2020; updates from collab partners in peritoneal metastasis & prostate exp 2020
Phase l or ll, Pre-Clinical Stage
Anti-infectives, Antivirals, Immuno-Oncology, Immunotherapy, Oncology
Platform Technology, Vaccine
Lilleakerveien 2 C
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Top 10 Holders of Targovax ASA
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by